Skip to main content
. 2024 Jan 25;12:3. doi: 10.1186/s40170-024-00332-8

Table 3.

Baseline characteristics stratified by CTI

Variables CTI < 4.71 CTI ≥ 4.71 P-value
(n = 763) (n = 649)
Sex (%) 0.066
 Male 466(61.1) 428(65.9)
 Female 297(38.9) 221(34.1)
 Age (mean (SD)) 58.27(11.66) 60.84(10.88)  < 0.001
 BMI (mean (SD)) 20.89(3.07) 21.17(3.31) 0.105
Tumor stage (%)  < 0.001
 I 52(6.8) 31(4.8)
 II 174(22.8) 58(8.9)
 III 255(33.4) 161(24.8)
 IV 282(37.0) 399(61.5)
Tumor.type (%)  < 0.001
 Lung cancer 169(22.1) 213(32.8)
 Gastric cancer 212(27.8) 102(15.7)
 Other digestive cancers 53(6.9) 66(10.2)
 Esophageal cancer 76(10.0) 53(8.2)
 Colorectal cancer 157(20.6) 120(18.5)
 Breast cancer 28(3.7) 18(2.8)
 Female reproductive cancer 19(2.5) 30(4.6)
 Urological cancer 12(1.6) 17(2.6)
 Nasopharyngeal cancer 26(3.4) 8(1.2)
 Other cancer 11(1.4) 22(3.4)
 Surgery, yes (%) 418(54.8) 266(41.0)  < 0.001
 Radiotherapy, yes (%) 62(8.1) 74(11.4) 0.047
 Chemotherapy, yes (%) 418(54.8) 383(59.0) 0.122
 Tch, mmol/L (mean (SD)) 4.46(1.04) 4.41(1.29) 0.396
 TG (mean (SD)) 1.15(0.49) 1.53(1.07)  < 0.001
 CRP (mean (SD)) 3.64(3.05) 50.33(51.47)  < 0.001
 CTI (mean (SD)) 4.14(0.41) 5.32(0.42)  < 0.001
 Glu (mean (SD)) 5.33(1.14) 6.05(2.21)  < 0.001
 Smoking, yes (%) 358(46.9) 353(54.4) 0.006
 drinking, yes (%) 196(25.7) 157(24.2) 0.558
 diabetes, yes (%) 45(5.9) 94(14.5)  < 0.001
 hypertension, yes (%) 115(15.1) 140(21.6) 0.002
 CHD, yes (%) 29(3.8) 37(5.7) 0.119
 KPS (mean (SD)) 85.54(11.42) 79.63(17.39)  < 0.001
 QC30 (mean (SD)) 47.85(12.87) 53.36(13.62)  < 0.001
ECOG PS (%)  < 0.001
  < 2 712(93.3) 522(80.4)
  ≥ 2 51(6.7) 127(19.6)
PGSGA (%) 0.003
 Well-nourished 8.89(3.92) 10.81(4.67)
 Malnutrition 722(94.6) 635(97.8)
 Nutrition intervention, yes (%) 160(21.0) 172(26.5) 0.017
 TSF (mean (SD)) 13.52(6.64) 13.53(7.03) 0.978

CTI CRP-TyG index, CRP C-reactive protein, TyG triglyceride-glucose index, BMI body mass index, CHD coronary heart disease, KPS karnofsky performance status, EORTC QLQ-C30 The European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Core 30 (QLQ-C30), ECOG PS eastern cooperative oncology group performance status, PGSGA Patient Generated Subjective Global Assessment, TSF triceps skinfold thickness